Compare Organon & Co. Common Stock (OGN) vs PayPal Holdings, Inc. (PYPL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs PayPal Holdings, Inc. — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while PayPal Holdings, Inc. trades at $56.17 (market cap $48.05B). The key difference: PayPal Holdings, Inc. is far larger — about 13.3× Organon & Co. Common Stock's market cap, and PayPal Holdings, Inc. pays the higher dividend (1%). Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and PayPal Holdings, Inc. for 106 Days on average.
| OGN | PYPL | |
|---|---|---|
Market Cap | $3.62B | $48.05B |
Volume | 2,892,999 | 7,905,570 |
Sector | Health | Financials |
52-Week High | $13.81 | $73.01 |
52-Week Low | $5.70 | $39.08 |
Typical Hold Time | 0 Days | 106 Days |
Enterprise Value | $11.04B | $50.20B |
Dividend Yield | 0.58% | 1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
PayPal (PYPL) trades at $56.17, up 0.21% today, with a bullish technical signal from moving averages and oscillators. The stock shows strong fundamentals with a low P/E of 10.62 and robust profitability, including a 14.36% net income margin. Recent earnings beat expectations in Q1 and Q2 2026, and a new partnership with Meta announced on September 22, 2026, has boosted investor optimism. Cash flow remains healthy, with net cash flow of $1.53 billion in 2025.
The outlook for PayPal is cautiously optimistic, supported by valuation discounts and strategic initiatives under new CEO Enrique Lores. However, risks include competitive pressures in digital payments and slowing growth in branded checkout. Analyst consensus is a 'Hold' with a $56.41 price target, reflecting mixed sentiment amid turnaround efforts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About PayPal Holdings, Inc.
PayPal Holdings, Inc. operates as a technology platform company that enables digital and mobile payments on behalf of consumers and merchants. The Company offers online payment solutions. PayPal Holdings serves customers worldwide.
Read more on PYPL →
